Tumor-Agnostic AKT Inhibition: Is It Time to AKT?

Basket trials of AKT-mutated tumors show that pan-AKT inhibitors are active in hormone receptor-positive breast cancer. There is mounting evidence for AKT inhibition in other tumor types, although small sample sizes limit evaluation of the tumor-agnostic potential for AKT inhibition. Emerging AKT1 E17K-specific molecules may improve tolerability and efficacy. See related article by McCourt et al., p. 4912.